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The interaction of DC-SIGN with gp120 provides an attractive target for intervention of HIV-1 transmission. Here, we have investigated
the potency of gp120 antibodies to inhibit the DC-SIGN–gp120 interaction. We demonstrate that although the V3 loop is not essential for
DC-SIGN binding, antibodies against the V3 loop partially inhibit DC-SIGN binding, suggesting that these antibodies sterically hinder DC-
SIGN binding to gp120. Polyclonal antibodies raised against non-glycosylated gp120 inhibited both low and high avidity DC-SIGN–gp120
interactions in contrast to polyclonal antibodies raised against glycosylated gp120. Thus, glycans present on gp120 may prevent the
generation of antibodies that block the DC-SIGN–gp120 interactions. Moreover, the polyclonal antibodies against non-glycosylated gp120
efficiently inhibited HIV-1 capture by both DC-SIGN transfectants and immature dendritic cells. Therefore, non-glycosylated gp120 may be
an attractive immunogen to elicit gp120 antibodies that block the binding to DC-SIGN. Furthermore, we demonstrate that DC-SIGN binding
to gp120 enhanced CD4 binding, suggesting that DC-SIGN induces conformational changes in gp120, which may provide new targets for
neutralizing antibodies.
D 2004 Elsevier Inc. All rights reserved.
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Human immunodeficiency virus type 1 (HIV-1) estab-
lishes persistent infections in humans caused by the
destruction of CD4+ T cells, which results in the develop-
ment of AIDS. Entry of HIV-1 into T cells requires the
interaction of the envelope glycoprotein gp120 with the
CD4 receptor and chemokine co-receptors, leading to
membrane fusion and virus entry. Upon primary infection,
dendritic cells (DCs) in mucosal tissues are thought to be the
first cells to be encountered by HIV-1. The presence of DCs0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this article.greatly enhances the efficiency of HIV-1 infection of CD4+
T cells, although DCs themselves are infected poorly
(Cameron et al., 1992; Pope et al., 1994). Recently, the
DC-specific intercellular adhesion molecule-3 (ICAM-3)
grabbing nonintegrin (DC-SIGN) has been identified to
mediate the initial capture of HIV-1 through its binding of
gp120 (Geijtenbeek et al., 2000b). After capture, DC-SIGN
transmits virus very efficiently to T cells in trans (Geijten-
beek et al., 2000b). The captured HIV-1 particles are
internalized by DCs, and remain in an infectious form in
an endocytic compartment for several days (Geijtenbeek et
al., 2000b; Kwon et al., 2002). Transmission to T cells can
take place through an dinfectious synapseT, where internal-
ized HIV-1 is concentrated at the interface between DC and
T cell (McDonald et al., 2003). The putative importance of
DC-SIGN in initial infection and dissemination suggests
that inhibiting the DC-SIGN–gp120 interaction provides an
attractive approach for intervention of HIV-1 transmission.04) 465–476
Table 1





(50 Ag/ml) on DC-SIGN
binding to gp120 BaL
697-D V2 (161–180) Ac
257-D IV V3 loop (305–309) A
268-D IV V3 loop (310–315) A
447-52D V3 loop (312–315) AA
F425 B4a1 V3 loop 0
F425 B4e8 V3 loop 0




F425 A1g8 CD4i 0
2G12 carbohydrates 0
a The effect of gp120 antibodies on DC-SIGN binding to gp120-coated
microtiter wells is shown. The values represent the relative binding of DC-
SIGN (0.75 Ag/ml) in the presence of the gp120 antibodies (50 Ag/ml),
compared to a 100% binding of DC-SIGN to gp120 in the absence of the
gp120 antibodies, data obtained from three independent experiments.
b gp120 amino acids are numbered according to the sequence of the
HXBc2 gp120 glycoprotein, where residue 1 is the methionine at the amino
terminus of the signal peptide.
c 0, 75 to 110% maximal binding (i.e., no effect); A, 50 to 74% of maximal
binding; AA, 25 to 49% of maximal binding.
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to the C-type lectin family (Geijtenbeek et al., 2000c), and
specifically binds to a characteristic internal feature of high-
mannose carbohydrate structure (Feinberg et al., 2001). In the
HIV-1 envelope glycoprotein gp120, five relative conserved
(C1–C5) regions and five variable regions (V1–V5) have
been identified (Kwong et al., 1998). Gp120 contains a
relatively large number of N-linked carbohydrates and
approximately 50% of the mass of gp120 can be attributed
to carbohydrate structures (Leonard et al., 1990; Zhu et al.,
2000). Since carbohydrates are clustered together on the outer
domain of the gp120 molecule, this region is weakly
immunogenic and known as the dsilentT face (Kwong et al.,
1998; Wyatt et al., 1998). Furthermore, it has been implicated
that the carbohydrate cluster forms a dglycan shieldT
preventing neutralizing antibodies from binding through
steric inhibition (Wei et al., 2003). Differential glycosylation
of the envelope glycoproteins affects DC-SIGN binding and
enhancement (Lin et al., 2000). Even though it is likely that
high-mannose structures on gp120 are recognized by DC-
SIGN (Hong et al., 2002; Lin et al., 2000; Lue et al., 2002),
protein–protein interactions may also be important in binding
(Geijtenbeek et al., 2002).
Strategies targeting DC-SIGN could help in combating
HIV-1 dissemination by blocking the DC-SIGN–HIV-1
interaction. However, DC-SIGN is involved in important
cellular functions (Van Kooyk and Geijtenbeek, 2003), and
we have demonstrated that using antibodies against DC-
SIGN to block HIV transmission will also prevent the
cellular functions of DC-SIGN (Geijtenbeek et al., 2000a,
2000b, 2000c). Therefore, antibodies against gp120 may
provide a powerful alternative to block DC-SIGN–HIV-1
interaction.
Here, we have investigated the potency of a panel of
monoclonal antibodies with defined epitopes on gp120 to
inhibit the DC-SIGN–gp120 interaction. We demonstrate
that although the V3 loop is not essential for DC-SIGN
binding, antibodies against the V3 loop partially inhibit
DC-SIGN binding. To investigate whether carbohydrates
on gp120 prevent the generation of blocking antibodies,
we compared the potency of polyclonal antibodies raised
against either glycosylated gp120 or non-glycosylated
gp120 to block the interaction of DC-SIGN with gp120.
Interestingly, polyclonal antibodies against non-glycosy-
lated gp120 could specifically block the high avidity DC-
SIGN–gp120 interaction without affecting the immunolog-
ical role of DC-SIGN. In future vaccination strategies, this
non-glycosylated gp120 may be used as an immunogen to
elicit blocking antibodies for the DC-SIGN–gp120 inter-
action. Finally, our data indicate that DC-SIGN induces
conformational changes in gp120 to enhance CD4 binding,
which may contribute to the DC-SIGN-mediated enhance-
ment of HIV-1 infection. These putative conformational
rearrangements in gp120 induced by DC-SIGN may
provide new targets for the generation of neutralizing
antibodies.Results
Effect of gp120-specific antibodies on the DC-SIGN–gp120
interaction
The interaction of DC-SIGN with gp120 provides an
attractive target for intervention with HIV-1 transmission. A
specific anti-DC-SIGN antibody can inhibit DC-SIGN
function, as anti-DC-SIGN antibodies efficiently inhibit
gp120 binding in low or high avidity interaction assays, the
ELISA-based DC-SIGN-Fc and the fluorescent beads
adhesion assays, respectively (Geijtenbeek et al., 2000b,
2002). However, blocking the role of DC-SIGN in HIV-1
transmission will inhibit the immunological function of DC-
SIGN (Geijtenbeek et al., 2000b, 2000c). Therefore, we
investigated the ability of antibodies against gp120 to block
the interaction with DC-SIGN. A panel of monoclonal
antibodies with defined epitopes on gp120 was used to
compete with DC-SIGN for binding to gp120. The ability of
antibodies in saturating concentrations to block the DC-
SIGN–gp120 interaction was measured in a low avidity DC-
SIGN–Fc adhesion assay. As summarized in Table 1,
although some gp120 antibodies were able to reduce the
binding of DC-SIGN to gp120, we did not observe a
complete block of the DC-SIGN–gp120 interaction.
The gp120 V3 loop antibodies
The gp120 V3 loop antibodies, 257-D IV, 268-D IV,
and 447-52D, interfered most strongly with DC-SIGN
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using gp120 derived from HIV-1 IIIB (data not shown).
Combinations of the V3 antibodies did not result in better
inhibition compared to the individual antibodies (data not
shown), which may be due to the overlapping epitopes of
the antibodies. The epitopes of these antibodies are
located between residues 305 to 315 of gp120, at the
tip of the V3 loop. The gp120 V3 loop, together with a
highly conserved element in the C4 domain, has been
implicated in chemokine receptor binding (Rizzuto et al.,
1998; Speck et al., 1997; Wyatt and Sodroski, 1998).
Inhibition was not observed for the V3 loop antibodies
F425-B4a1 and F425B4e8, which are directed to epitopes
at the base of the V3 loop (Cavacini et al., 2003). A
decrease in DC-SIGN binding to gp120 was observed
with the 697-D antibody directed to a conformational
epitope in the V2 loop. A combination of the blocking V3
257-D IV and V2 697-D antibodies did not result in a
stronger inhibition (data not shown). The 670-D antibody
directed to the C5 region also exerted a minor inhibition,Fig. 1. DC-SIGN binding to the HIV-1 gp120DV1/V2 DV3 mutant. The ability of
assessed in a DC-SIGN-Fc adhesion assay. (A) The captured gp120 glycoproteins,
with the indicated gp120 antibodies (1 Ag/ml), and detected as described with H
binding to captured gp120 glycoproteins was measured (black bars) and inhibitio
and the anti-gp120 antibody 2G12 (white bars). One representative experiment out
and DV1/V2/DV3. DC-SIGN transfectants were incubated with gp120-coated b
determined using antibodies against DC-SIGN (AZN-D1). One representative expalthough this was not observed using gp120 derived from
other HIV-1 strains (data not shown). In summary, only
the V3 loop antibody 447-52D could significantly inhibit
binding of DC-SIGN. This suggests that interactions of
DC-SIGN with gp120 may take place in close proximity
of the V3 loop.
To further analyze the role of the gp120 V3 loop in the
DC-SIGN–gp120 interaction, we tested binding of DC-
SIGN to a V3 loop deletion mutant of gp120. This
deletion was introduced in the gp120DV1/V2 protein of
the HIVYU2 strain that lacks the V1/V2 variable loops of
the gp120 glycoprotein (Rizzuto et al., 1998). Both the
gp120DV1/V2 and gp120DV1/V2DV3 mutant proteins
were transiently produced by transfection of 293T cells.
Integrity of the V3 loop deletion mutant was confirmed by
binding of CD4 binding site (CD4bs) antibody IgG1b12 to
the gp120DV1/V2DV3 mutant protein and absence of the
V3 loop antibody 447-52D epitope (Fig. 1A). The CD4-
induced (CD4i) antibody 48d also did not bind, as
previously reported (Xiang et al., 2002) (Fig. 1A). BothDC-SIGN to bind the gp120DV1/V2 and gp120DV1/V2DV3 mutants was
gp120DV1/V2 (black bars), gp120DV1/V2DV3 (gray bars) were incubated
RP-labeled goat-anti human IgG antibody. (B) DC-SIGN-Fc (0.75 Ag/ml)
n was investigated using thee anti-DC-SIGN antibody AZN-D1 (gray bars)
of three is shown. (C) Cellular DC-SIGN binds the gp120 mutants DV1/V2
eads and the binding was measured by flow cytometry. Specificity was
eriment out of two is shown.
Fig. 2. Binding of DC-SIGN and 2G12 to gp120 glycoproteins of different
HIV-1 strains. Binding of the 2G12 antibody (1 Ag/ml; black bars) to gp120
glycoproteins of HIV-1 strains BaL and CM235 (1 Ag/ml gp120) was
assessed by ELISA. Using the soluble DC-SIGN–Fc adhesion assay,
binding of soluble DC-SIGN–Fc was also evaluated (gray bars). Binding
could be blocked by pre-incubation of DC-SIGN–Fc with anti-DC-SIGN
antibody AZN-D1 (white bars).
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bind the gp120 mutants DV1/V2 and DV1/V2DV3 (Figs.
1B and C). Binding could specifically be inhibited with the
anti-DC-SIGN antibody AZN-D1, but not with the anti-
body against 2G12 (Figs. 1B and C). Notably, although the
V2 loop antibody 697-D interfered with DC-SIGN binding
to gp120 (Table 1), DC-SIGN was able to bind the
gp120DV1/V2 protein, lacking the V1/V2 loops.
These data indicated that both the V3 loop antibodies and
the V2 loop antibody presumably sterically hinder the DC-
SIGN–gp120 interaction, as both the V2 loop and the V3
loop are not essential for DC-SIGN binding to gp120.
The CD4bs and CD4i antibodies
The CD4bs antibodies F105 and IgG1b12 that compete
with CD4 for binding gp120 (Moore and Sodroski, 1996)
did not block the binding of DC-SIGN. The 654-D
antibody caused a decrease in DC-SIGN binding to
gp120. Carbohydrates are implicated in the 654-D epitope,
which could explain the interference of the 654-D
antibody with the DC-SIGN binding to gp120 (Gorny et
al., 1994).
CD4 binding to gp120 exposes epitopes that are
recognized by the CD4i antibody F425 A1g8. This antibody
can also bind in the absence of CD4 with a lower affinity
and inhibits binding of gp120 to the chemokine receptor
(Xiang et al., 2002). We observed no significant interference
with the DC-SIGN–gp120 interaction using the CD4i
antibodies (Table 1). These data demonstrate that CD4bs
and CD4i antibodies do not efficiently block the DC-SIGN–
gp120 interaction, indicating that the CD4 binding site and
the CD4i epitope are not directly involved in the interaction
with DC-SIGN.
The carbohydrate-dependent antibody 2G12
The human monoclonal antibody 2G12 has previously
been demonstrated to bind to a carbohydrate-dependent
epitope on gp120 (Scanlan et al., 2002). 2G12 has a
multivalent interaction with a conserved cluster of
Man(a)1–2Man-linked high-mannose type carbohydrates
on gp120 (Calarese et al., 2003). A similar structure is
present in the mannose-cap of ManLAM, a mycobacterial
cell wall component that is a known ligand for DC-SIGN
(Geijtenbeek et al., 2003).
However, 2G12 was not able to block the binding of
DC-SIGN to gp120 (Table 1). Next, we investigated
binding of both 2G12 and DC-SIGN to gp120 glycopro-
teins of another HIV-1 strain, since it has been demon-
strated that 2G12 does not recognize clade E HIV-1 strains
(Scanlan et al., 2002). Indeed, we did not observe binding
of 2G12 to the clade E gp120CM235 (Fig. 2), whereas DC-
SIGN efficiently interacted with the clade E gp120CM235
glycoprotein, indicating that the 2G12 epitope is not
recognized by DC-SIGN.Polyclonal antibodies raised against non-glycosylated
gp120 can block the DC-SIGN–gp120 interaction
Monoclonal gp120 antibodies only gave partial inhib-
ition of the DC-SIGN–gp120 interaction. Moreover, the
antibodies able to interfere with DC-SIGN-Fc binding to
gp120 were not able to interfere with gp120 binding to
cellular DC-SIGN due to the high avidity of cellular
tetrameric DC-SIGN for gp120. We hypothesized that the
glycan shield of gp120 may prevent the generation of
blocking antibodies. Therefore, we compared the potency of
polyclonal antibodies raised against either glycosylated
gp120 or non-glycosylated gp120 to block the interaction
of DC-SIGN with gp120.
The binding characteristics of polyclonal antibody
mixtures raised against gp120 and non-glycosylated gp120
were assessed by means of ELISA (Fig. 3). The polyclonal
antibodies raised against gp120 recognized both glycosy-
lated and non-glycosylated gp120. Binding to both forms of
gp120 was also observed for the polyclonal antibodies
raised against non-glycosylated gp120, demonstrating that
epitopes recognized by the polyclonal antibodies raised
against non-glycosylated gp120 are exposed in glycosylated
gp120. Furthermore, the antibodies raised against both non-
glycosylated and glycosylated gp120 bound to a similar
extent to glycosylated gp120.
Next, we investigated the potency of these polyclonal
antibodies to block the DC-SIGN–gp120 interaction. Poly-
clonal antibodies raised against both glycosylated and non-
glycosylated gp120 were equally efficient in inhibiting the
DC-SIGN–gp120 interaction in the low avidity DC-SIGN–
Fc adhesion assay (Fig. 4A).
Fig. 3. Binding characteristics of the polyclonal antibodies raised against wild type and non-glycosylated gp120. Binding of polyclonal antibodies raised
against gp120 (open) and non-glycosylated gp120 (filled) to gp120 (circles) and non-glycosylated gp120 (squares) by ELISA. Different dilutions of the
polyclonal antibodies were tested. Binding was detected with an HRP-labeled mouse-anti goat IgG antibody.
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efficient in blocking the recombinant DC-SIGN binding,
we tested inhibition of cellular DC-SIGN binding to
polyvalent gp120 by the polyclonal antibody mixtures in
the high avidity fluorescent beads adhesion assay (Fig. 4B).
Strikingly, gp120 binding to immature DCs was inhibited in
the presence of polyclonal antibodies raised against non-
glycosylated gp120 to a similar extent as an antibody
against DC-SIGN. This inhibition was specific since the
polyclonal antibodies did not block binding of DC-SIGN to
the cellular ligand ICAM-3. In contrast, the addition of the
polyclonal antibodies raised against glycosylated gp120
caused only a minor inhibition of the binding of gp120 to
immature DCs. In order to investigate the specificity of the
polyclonal antibodies for gp120 and exclude any other
components that may interfere with DC-SIGN binding, DC-
SIGN transfectants were incubated with gp120-coated
beads, which had been pre-incubated with the different
antibodies and extensively washed to remove unbound
antibodies (Fig. 4C). DC-SIGN–gp120 binding was blocked
by treating the gp120-coated beads with polyclonal anti-
bodies against non-glycosylated gp120, whereas both
polyclonal antibodies against gp120 and pooled normal
goat serum did not inhibit the interaction (Fig. 4C). As
expected, antibodies against DC-SIGN were only able to
inhibit the interaction when pre-incubated with cells but not
with gp120 beads (Fig. 4C). These results demonstrate that
polyclonal antibodies against non-glycosylated gp120 block
the gp120 interaction with DC-SIGN by specifically binding
to gp120. Moreover, the polyclonal antibodies raised against
non-glycosylated gp120 SF-2 demonstrated a broad specif-
icity, since the antibodies inhibited DC-SIGN binding to
gp120 derived from different HIV-1 strains (Fig. 4D).
In order to asses their ability to prevent DC-SIGN
binding to trimeric gp120 as present on viruses, we
investigated the ability of the antibodies to inhibit HIV-1
capture by both DC-SIGN transfectants and immature
dendritic cells. DC-SIGN transfectants captured wholeHIV-1 virions as measured by a p24gag ELISA (Fig. 4E).
The capture was blocked by the polyclonal antibodies
against non-glycosylated gp120 to a similar extent as
observed with both EGTA and antibodies against DC-SIGN
(Fig. 4E). Moreover, the polyclonal antibodies against non-
glycosylated gp120 also completely inhibited virus capture
by immature DCs, similarly as antibodies against DC-SIGN
(Fig. 4E).
In summary, the polyclonal antibodies raised against
non-glycosylated gp120 could specifically block the DC-
SIGN–gp120 interaction, and prevent HIV-1 capture by
DCs. These promising results may lead to the use of non-
glycosylated gp120 as an immunogen to elicit blocking
antibodies to prevent HIV-1 capture by DC-SIGN.
Distinct binding sites on gp120 for DC-SIGN and CD4
The receptor binding site for CD4 on gp120 is a highly
conserved region and has been characterized extensively
(Kwong et al., 1998). As the CD4bs antibodies were not
able block the DC-SIGN-gp120 interaction (Table 1), we
analyzed binding of soluble human CD4 (sCD4) to gp120 in
the presence of DC-SIGN using an ELISA-based binding
assay. Binding of sCD4 to gp120 was examined using a
CD4 antibody that does not interfere with the gp120 binding
site on CD4. As seen in Fig. 5A, binding of sCD4 to gp120
was not inhibited by pre-incubation of gp120 with DC-
SIGN, demonstrating that DC-SIGN binding to gp120 did
not interfere with the interaction of CD4 with gp120. Next,
we examined whether CD4 could bind to gp120 that has
been captured by cellular DC-SIGN (Fig. 5B). We observed
binding of CD4 to immature DCs when gp120 was present,
but not when gp120 was absent. This corroborates our
observation with the ELISA-based binding assay, demon-
strating that simultaneous binding of DC-SIGN and CD4 to
gp120 can take place. Binding was inhibited when cells
were pre-incubated with an anti-DC-SIGN antibody that
blocks the binding of gp120 to DC-SIGN, demonstrating
Fig. 4. Polyclonal antibodies raised against non-glycosylated gp120 inhibit HIV-1 binding to DC-SIGN. (A) For the DC-SIGN–Fc adhesion assay, gp120-
coated wells were incubated with the polyclonal antibodies (1:100 dilution) or AZN-D1 (80 Ag/ml), followed by DC-SIGN–Fc, without washing. (B) For the
fluorescent beads adhesion assay, immature DCs were incubated with the polyclonal antibodies (1:10 dilution). Next, binding of the gp120-coated beads (black
bars) and ICAM-3-coated beads (gray bars) in the presence of the polyclonal antibodies to cellular DC-SIGN was assessed. (C) The polyclonal antibodies
against non-glycosylated gp120 specifically block the gp120–DC-SIGN interaction. Fluorescent gp120-coated beads are preincubated with the antisera for 20
min at 37 8C. The beads are washed and added to DC-SIGN transfectants (THP-DC-SIGN). Adhesion is measured after 45 min at 37 8C. (D) The polyclonal
antibodies against non-glycosylated gp120 inhibit binding of DC-SIGN to different strains of HIV-1 gp120. The binding assay was performed as described in
(B). (E) The polyclonal antibodies against non-glycosylated gp120 inhibit HIV-1 binding to cellular DC-SIGN. Both immature DCs and THP-DC-SIGN
transfectants are incubated with HIV-1 JR-CSF (p24 100 ng/100.000 cells) for 60 min at 37 8C in presence of different antibodies. Binding is measured after
washing and lysing the cells using a p24 ELISA.
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Fig. 5. Simultaneous binding of CD4 and DC-SIGN to gp120. (A) Binding of sCD4 (0.5 Ag/ml) to gp120-coated wells in the presence of DC-SIGN–Fc, was
determined using the CD4v4 antibody that does not bind to the gp120 binding site on CD4. Standard deviation b0.02. (B) Simultaneous binding of DC-SIGN
and CD4 to gp120 was also determined using the fluorescent beads adhesion assay. Monomeric gp120 (5 Ag/ml) was added to immature DCs. Binding of the
CD4-coated fluorescent beads to gp120 was analyzed. CD4 binding in the absence of gp120 (white bars); CD4 binding in the presence of gp120 (black bars);
binding of CD4 was absent when cells were pre-incubated with anti-DC-SIGN antibody AZN-D1 (20 Ag/ml) (gray bars). One representative experiment of
three is shown.
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demonstrated that CD4 and DC-SIGN have distinct binding
sites on gp120.
Enhanced CD4 binding to gp120 induced by DC-SIGN
Next, we examined whether DC-SIGN binding to gp120
could modulate binding of CD4 to gp120 in an ELISA-
based binding assay. The molecular mechanism by which
DC-SIGN enhances the infection of T cells is not fully
understood. Therefore, besides concentrating virus particles
on the surface of DCs, DC-SIGN may induce conforma-
tional changes in gp120 that enable a more efficient
interaction of gp120 with CD4 by influencing conforma-
tional masking. The DC-SIGN-dependent enhancement ofFig. 6. Enhancement of CD4 binding to gp120 by the DC-SIGN–gp120
interaction. CD4 binding to gp120 captured onto microtiter wells using the
D7324 antibody was assessed in the presence of DC-SIGN (0.75 Ag/ml),
with or without the DC-SIGN inhibiting polysaccharide mannan using
different concentrations of sCD4. One representative experiment of three is
shown.HIV-1 infection led us to investigate whether DC-SIGN
binding to gp120 induces an increase of CD4 binding to
gp120 (Geijtenbeek et al., 2000b).
As seen in Fig. 6, binding of CD4 to gp120 was
increased upon DC-SIGN interaction with gp120. We
demonstrate that in the presence of DC-SIGN, less CD4
was required for a similar extent of binding to gp120
compared to CD4 alone, suggesting that DC-SIGN binding
to gp120 increased binding of CD4 to gp120. The increase
is not due to cross-reactivity of the secondary anti-mouse
antibody to the human IgG1 Fc region of DC-SIGN Fc,
since no binding is observed in the absence of sCD4. The
increased binding is specific for DC-SIGN binding to gp120
since it was not observed when DC-SIGN binding to gp120
was inhibited with the polysaccharide mannan (Fig. 6). In
the presence of DC-SIGN, an increase in CD4 binding to
gp120 of 145–200% was repeatedly observed. The gp120
glycoprotein is very flexible and it seems likely that
conformational changes in gp120 are induced upon binding
of DC-SIGN thereby enhancing CD4 binding. This appears
analogous to CD4 that triggers conformational reorganiza-
tion in gp120 allowing high-affinity binding to the chemo-
kine receptor (Sattentau et al., 1993; Wu et al., 1996).Discussion
The important role of DC-SIGN in HIV-1 transmission
makes it an attractive target to intervene with HIV-1
dissemination. Blocking antibodies against DC-SIGN
inhibit HIV-1 capture by DCs (Geijtenbeek et al., 2000b),
but also interfere with the immunological role of DC-SIGN
(Geijtenbeek et al., 2000a, 2000b). Therefore, inhibitors
targeting HIV-1 gp120 to prevent DC-SIGN capture seem
warranted to interfere with HIV-1 dissemination. More
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for development of these inhibitors. Here, we have
investigated the potency of monoclonal and polyclonal
antibodies against gp120 to inhibit this interaction.
We have evaluated specific competition of DC-SIGN
with antibodies against gp120. Our results demonstrate that
defined monoclonal gp120 antibodies could not completely
inhibit the interaction of DC-SIGN with gp120. V3 loop
antibodies that recognize the tip of the loop (Gorny et al.,
1997) reduced binding of DC-SIGN up to 50%, in contrast
to the V3 loop antibodies directed to the base of the loop
that had no effect on DC-SIGN binding to gp120. However,
the V3 loop itself is not involved in the interaction with DC-
SIGN, as DC-SIGN binding was not affected by deletion of
the V3 loop from gp120. Thus, V3 loop antibodies might
modulate DC-SIGN binding by sterically hindering DC-
SIGN from accessing its binding site. N-linked glycosyla-
tion high mannose structures, but not complex oligosac-
charide structures, are specifically recognized by DC-SIGN
(Feinberg et al., 2001), and studies on the gp120 carbohy-
drate composition indicate that high mannose structures are
observed on the gp120 core closely clustered to the V3 loop
(Zhu et al., 2000). Our inhibition data indicate that DC-
SIGN interacts with these carbohydrates in relative close
proximity to the V3 loop. The 2G12 gp120 antibody binds
to specific conserved cluster of high-mannose type carbo-
hydrates on gp120 in proximity of the V3 loop, which could
be involved in DC-SIGN binding. However, we did not
observe inhibition of the DC-SIGN–gp120 interaction by
2G12. This data was supported by results showing that DC-
SIGN binds to clade E gp120CM235 that lacks the 2G12
epitope. This is in agreement with the data of Hong et al.
(2002), demonstrating that DC-SIGN and 2G12 have
distinct binding sites on gp120. Future studies could include
the use of antigen-binding fragments of the antibody instead
of the entire antibody to minimize the effect of steric
hindrance caused by the size of the antibody.
Our data demonstrate that monoclonal gp120 antibodies
do not block the DC-SIGN–gp120 interaction efficiently.
We hypothesized that the presence of a glycan shield may
prevent the generation of blocking antibodies. Therefore, we
have investigated the potency of polyclonal antibodies
raised against both glycosylated and non-glycosylated
gp120 to inhibit binding of DC-SIGN to gp120. Although
both polyclonal antibodies raised against either glycosylated
and non-glycosylated gp120 reacted similarly to glycosy-
lated gp120 (Fig. 3), we observed differences in the
blocking of the DC-SIGN–gp120 interaction (Fig. 4).
Polyclonal antibodies against glycosylated gp120
inhibited the DC-SIGN–gp120 interaction in the low avidity
interactions ELISA-based DC-SIGN–Fc adhesion assay, but
not in the high avidity fluorescent beads adhesion assay
requiring binding of polyvalent gp120 to cellular DC-SIGN.
In contrast, polyclonal antibodies raised against non-
glycosylated gp120 inhibited binding of gp120 to DC-
SIGN in both assays. Thus, polyclonal antibodies raisedagainst non-glycosylated gp120 have a high affinity for
gp120 or may be directed to gp120 structures that become
exposed when carbohydrates are absent. This suggests that
the glycan shield formed by the carbohydrate cluster on
gp120 (Koch et al., 2003), in addition to preventing binding
of neutralizing antibodies, might also prevent the generation
of gp120 antibodies against the DC-SIGN binding site.
DC-SIGN plays an important cellular function by
mediating adhesion of DCs to T cells through ICAM-3
binding. Antibodies raised against non-glycosylated gp120
inhibit the gp120–DC-SIGN interaction without altering the
immunological function of DC-SIGN (Fig. 4). These
polyclonal antibodies evidently bind gp120 in a way that
inhibits DC-SIGN binding. Furthermore, the polyclonal
antibodies against non-glycosylated gp120 were able to
inhibit capture of HIV-1 by both DC-SIGN transfectants and
immature DCs to a similar level as observed with antibodies
against DC-SIGN (Fig. 4). Thus, the polyclonal antibodies
efficiently block the interaction of DC-SIGN to both
monomeric and trimeric gp120 as present on viruses. Even
though the precise nature of the blocking capability of the
polyclonal antibodies against the non-glycosylated gp120
remains yet to be identified, these data hold promise for the
future. In vaccination strategies, it may be feasible to target
a defined structure on gp120 to block DC-SIGN binding to
elicit blocking antibodies, while the binding of cellular
ligands to DC-SIGN remains unaffected.
It has recently been suggested that CD4 and DC-SIGN
compete for gp120 binding (Nobile et al., 2003). In contrast,
we have demonstrated that the primary HIV-1 receptor CD4
and DC-SIGN can bind simultaneously to gp120, establish-
ing that the DC-SIGN binding site is distinct from the CD4
binding site on gp120 (Fig. 5). Similar results were obtained
with a K562 transfectant expressing DC-SIGN (data not
shown). This was supported by data demonstrating that
CD4bs antibodies did not block the DC-SIGN–gp120
interaction (Table 1).
Binding of DC-SIGN to gp120 on HIV-1 is implicated to
increase the local concentrations of virus particles on the DC
surface in the proximity of entry receptors (Lee et al., 2001;
Pohlmann et al., 2001a, 2001b; McDonald et al., 2003).
Here, we have demonstrated that DC-SIGN binding to
gp120 increases CD4 binding to gp120, suggesting that DC-
SIGN induces conformational changes that favor CD4
binding. Hence, DC-SIGN may not merely act to concen-
trate virus at the cell surface but may also increase CD4
binding to gp120.
Furthermore, besides a glycan shield to mask the
potential vulnerable CD4 receptor binding site on gp120
to escape neutralization, conformational masking has been
suggested to protect the receptor binding site (Kwong et al.,
2002). This conformational masking influences the effi-
ciency with which CD4 binding site antibodies are
generated. It is tempting to speculate that this strategy to
evade recognition by the immune system might also affect
the binding of the CD4 receptor itself. Therefore, DC-SIGN
A.N. Lekkerkerker et al. / Virology 329 (2004) 465–476 473may play an essential role by enhancing CD4 binding to
gp120. Taken together, the observed increased binding of
gp120 to CD4 provides an additional explanation for DC-
SIGN in enhancement of HIV-1 transmission. Future studies
are required to investigate this intriguing possibility.
In summary, this study contributes to further under-
standing of the DC-SIGN–gp120 interaction. More impor-
tantly, these data will be valuable in the development of
novel inhibitory agents to prevent capture of HIV-1 by DC-
SIGN in future vaccination strategies.Material and methods
Proteins and plasmids
The following proteins were obtained through the NIH
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH: HIV-1IIIB gp120, HIV-1BaL gp120,
and HIV-1CM235 gp120, whereas sCD4 was from Dr.
Norbert Schuelke. Recombinant HIV-1SF2 gp120 (Haig-
wood et al., 1990a; Levy et al., 1984; Sanchez-Pescador et
al., 1985; Scandella et al., 1993) (lot 33MJE191) expressed
in CHO cells and HIV-1SF2 gp120 (Env 2–3) (Haigwood et
al., 1990b; Steimer et al., 1986) (lot 11 MGC014), a full-
length non-glycosylated polypeptide analog of gp120
produced in yeast, were obtained from Chiron Corporation,
Emeryville, CA. Plasmid encoding the gp120-Fc from the
JR-FL isolate was obtained through the NIH. Plasmids
encoding the gp120DV1/V2 protein from the HIV-1YU2
isolate, lacking the 52 N-terminal residues and the V1/V2
variable loops, and the gp120DV1/V2DV3 (D298–329),
containing a deletion of the V3 variable loop of gp120, were
a generous gift from Dr. J. Sodroski, Dana-Farber Cancer
Institute, Boston (Xiang et al., 2002). Plasmids encoding
CD4-Fc and ICAM-3-Fc were kindly provided by Dr. D.L.
Simmons, Institute of Molecular Medicine, Oxford, United
Kingdom.
Antibodies
The following monoclonal antibodies against HIV-1
were obtained through the NIH AIDS Research and
Reference Reagent Program: 257-D IV, 268-D IV (Gorny
et al., 1991, 1993), 447-52D (Conley et al., 1994), 697-D
(Gorny et al., 1994), 654-D (Zolla-Pazner et al., 1995), and
670-D (Zolla-Pazner et al., 1995) from Dr. Susan Zolla-
Pazner F425 A1g8, F425 B4a1, F425 B4e8 (Cavacini et al.,
2003), and F105 (Cavacini et al., 1993; Posner et al., 1993)
from Dr. Marshall Posner and Dr. Lisa Cavacini, 2G12
(Trkola et al., 1996) from Dr. Hermann Katinger, 48d
(Moore et al., 1993; Thali et al., 1993) from Dr. James
Robinson, IgG1b12 (Roben et al., 1994) from Dr. Dennis
Burton and Carlos Barbas. Polyclonal antibodies against
HIV-1SF2 gp120 and polyclonal antibodies against non-
glycosylated HIV-1SF2 gp120 were obtained from ChironCorporation (Haigwood et al., 1990a; Levy et al., 1984;
Sanchez-Pescador et al., 1985; Scandella et al., 1993). The
polyclonal antibodies were pooled bleedings from nine
animals, and contained similar amounts of IgG (data not
shown). The polyclonal sheep antibody D7324, raised
against a synthetic peptide representing the 15 C-terminal
amino acids of HIV-1IIIB gp120 was purchased from Aalto
Bio Reagents (Dublin, Ireland).
The mouse anti-DC-SIGN antibodies AZN-D1 and
AZN-D2 were generated in our laboratory (Geijtenbeek
et al., 2000b, 2000c). The mouse antibody DC28, directed
against the neck domain of the repeat region of DC-SIGN,
was a generous gift from Dr. J.A. Hoxie, Department of
Medicine, University of Pennsylvania, Philadelphia. The
mouse anti-CD4 antibody CD4v4 was obtained from
Becton Dickinson (Alphen aan de Rijn, The Netherlands).
A horseradish peroxidase (HRP) labeled goat-anti mouse
IgG antibody (Jackson Immunoresearch, West Grove, PA,
USA) was used to detect the above-mentioned antibodies.
The HRP-labeled goat-anti human IgG antibody (Jackson
Immunoresearch) was used to detect DC-SIGN–Fc in the
soluble DC-SIGN–Fc adhesion assays. HRP-labeled
mouse-anti goat IgG antibody (Sigma-Aldrich, Zwijn-
drecht, The Netherlands) was used to detect the polyclonal
antibodies against HIV-1SF2 gp120 and non-glycosylated
HIV-1SF2 gp120.
Cells
Immature DCs were cultured from monocytes in the
presence of 500 U/ml IL-4 and 800 U/ml GM-CSF (both
from Schering-Plough, Amstelveen, The Netherlands) as
previously described (Geijtenbeek et al., 2000c).
Transient expression of gp120 variants
Transient transfection of 4 Ag of the plasmid encoding
either the gp120DV1/V2 protein or the gp120DV1/V2DV3
protein, with 1 Ag of the plasmid encoding the HIV-1 Tat
protein, or 4 Ag of the plasmid encoding gp120JR-FL-Fc
protein, or CD4-Fc protein or ICAM-3-Fc protein in the
293T cell line were carried out using Lipofectamin
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. At 3 days post-transfection, culture super-
natants containing the proteins of interest were collected,
cleared by centrifugation and stored at 20 8C.
Fluorescent beads adhesion assay
Carboxylate-modified TransFluorSpheres (488/645 nm,
1.0 Am; Molecular Probes, Eugene, OR) were coated with
native gp120, or CD4-Fc, gp120-Fc, or ICAM-3-Fc proteins
containing medium of the transient transfection in 293T
cells. The beads were prepared as previously described
(Geijtenbeek et al., 2000b, 2002). DC-SIGN binding
characteristics of gp120-Fc-beads from the HIV-1JR-FL strain
A.N. Lekkerkerker et al. / Virology 329 (2004) 465–476474were similar as observed with native gp120-coated beads.
Specificity was determined in the presence of 80 Ag/ml anti-
DC-SIGN antibody AZN-D2. Binding of CD4-coated beads
to immature DCs was carried out in the presence of 5 Ag/ml
gp120MN. The fluorescent beads adhesion assay was
performed essentially as described (Geijtenbeek et al.,
2000b, 2002).
Soluble DC-SIGN-Fc adhesion assay
All experiments were carried out with a soluble
recombinant DC-SIGN-Fc chimera and gp120IIIB, unless
stated otherwise. DC-SIGN-Fc consists of the extracellular
portion of DC-SIGN fused at the COOH terminus to a
human IgG1-Fc fragment (Geijtenbeek et al., 2002) and is
produced in CHO cells. This soluble DC-SIGN–FC
chimera is functional as previously demonstrated (Geijten-
beek et al., 2002). In the DC-SIGN–Fc adhesion assay, flat
bottom microtiter-plate wells (Maxisorb; Nunc, Copenha-
gen, Denmark) were coated overnight at 4 8C with gp120
(0.5 Ag/ml) or gp120 antibody D7324 directed to the C5
region (Aalto Bioreagents) at a concentration of 10 Ag/ml
(500 ng/well) diluted in 0.2 M NaHCO3 buffer pH 9.2,
followed by blocking with 1% bovine serum albumin for 30
min at 37 8C. If D7324 was used, gp120 (0.5 Ag/ml) was
subsequently captured for 60 min at room temperature.
Soluble DC-SIGN–Fc supernatant (1.5 Ag/ml) diluted 1:2 in
TSM (20 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM
CaCl2, 2 mM MgCl2) was added, and adhesion was
performed for 90 min at 37 8C. Bound DC-SIGN–Fc was
detected with HRP labeled goat-anti human IgG antibody.
Specificity was determined in the presence of 80 Ag/ml
AZN-D1, 5 Ag/ml mannan, or 5 mM EGTA.
To assess the ability of gp120 antibodies to compete with
binding of DC-SIGN–Fc to gp120, gp120-coated wells were
incubated with the indicated gp120 antibodies (50 Ag/ml,
1:100 dilutions for antibody supernatants) for 90 min at
room temperature to obtain maximal binding, followed by
soluble DC-SIGN–Fc supernatant diluted in TSM incuba-
tion for another hour at room temperature. DC-SIGN–Fc
bound to gp120 was detected using the DC28 antibody (1
Ag/ml), followed by HRP labeled goat-anti-mouse IgG
antibody.
ELISA
Flat bottom microtiter-plate wells (Maxisorb; Nunc,
Copenhagen, Denmark) were coated overnight at 4 8C with
gp120 (0.5 Ag/ml) as indicated or gp120 antibody D7324
directed to the C5 region (Aalto Bioreagents) at a concen-
tration of 10 Ag/ml (500 ng/well) diluted in 0.2 M NaHCO3
buffer pH 9.2, followed by blocking with 1% bovine serum
albumin for 30 min at 37 8C. If D7324 was used, culture
supernatants containing proteins of interested diluted 1:2 in
TSM were subsequently captured for 60 min at room
temperature. Next, antibodies of interest were added for 60min at room temperature. Bound antibodies were detected
with a suitable HRP labeled secondary antibody.
CD4-DC-SIGN–Fc binding assay
For the CD4-DC-SIGN–Fc binding assay, gp120 was
captured with D7324, and DC-SIGN–Fc (0.75 Ag/ml) was
added and incubated for 1 h at room temperature. After
washing, the wells were incubated with sCD4 (0.5 Ag/ml)
for 1 h at room temperature. CD4 binding was detected
using CD4v4 antibody (1 Ag/ml), followed by HRP labeled
goat-anti-mouse IgG antibody depleted of cross-reactivity to
human IgG1 (Jackson Immunoresearch). To assess the
modulation of CD4 upon binding of DC-SIGN–Fc to
gp120, no wash was performed after addition of DC-
SIGN–Fc. Specificity was determined by pre-incubation of
DC-SIGN for 15 min with mannan (5 Ag/ml).
HIV-1 capture by immature DCs
Cells (100.000) were incubated with HIV-1 JR-CSF (100
ng of p24gag) for 60 min at 37 8C. Specificity was
determined in the presence of 20 Ag/ml anti-DC-SIGN
antibody AZN-D1, polyclonal antiserum against non-gly-
cosylated gp120 (1:50), or EGTA (5 mM). The cells were
washed twice and subsequently lysed and virus binding was
determine by measuring the p24 concentration using the
p24gag detection kit as described by the manufacturer
(Beckman-Coulter, Mijdrecht, The Netherlands).Acknowledgments
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